The pharmacology of VA21B7 : an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models

• Published in: Psychopharmacologia 1995, Vol.117 (2), p.137-148
• Main Authors: ARTAIZ, I, ROMERO, G, ZAZPE, A, MONGE, A, CALDERO, J. M, ROCA, J, LASHERAS, B, DEL RIO, J
• Format: Article
• Language: English
• Subjects: Analgesics - pharmacology; Animals; Anti-Anxiety Agents - pharmacology; Anticonvulsants - pharmacology; Behavior, Animal - drug effects; Biological and medical sciences; Drinking Behavior - drug effects; Exploratory Behavior - drug effects; Guinea Pigs; Heart Rate - drug effects; In Vitro Techniques; Indoles - pharmacology; Male; Medical sciences; Mice; Motor Activity - drug effects; Muscle Contraction - drug effects; Muscle, Smooth - drug effects; Muscle, Smooth, Vascular - drug effects; Neuropharmacology; Pharmacology. Drug treatments; Piperazines - pharmacology; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; Radioligand Assay; Rats; Rats, Wistar; Serotonin Antagonists - pharmacology
• ISSN: 0033-3158; 1432-2072
• DOI: 10.1007/BF02245179

VA21B7 (3-[2-(4'-piperonylpiperazinyl) indolyl] carboxaldehyde) was synthesized as a potential 5-HT3 receptor antagonist. Even though VA21B7 showed a higher affinity towards 5-HT3 receptors as compared to other receptors studied, it was not a potent 5-HT3 receptor antagonist either in the periphery or in the brain. In a simple animal model of anxiety such as the two-compartment box in mice, a remarkable anxiolytic-like effect was found at doses of 2-500 micrograms/kg IP and also at low oral doses, in the microgram range. These drug doses did not produce any significant effect on spontaneous motor activity of mice. The anxiolytic profile of VA21B7 was further explored using other models of anxiety in rats such as the elevated plus-maze and punished-drinking. VA21B7 was compared with standard 5-HT3 receptor antagonists such as ondansetron, tropisetron and granisetron, with the 5-HT1A agent buspirone and with diazepam. In the plus-maze, VA21B7 showed an anxiolytic-like profile after doses of 0.25-0.5 mg/kg IP or 2-4 mg/kg PO which did not modify the number of total entries into the open and closed arms of the maze. Diazepam, granisetron and tropisetron were also effective in this test but not ondansetron and buspirone. VA21B7 was also able to release suppressed behaviour in the punished-drinking test. The dose-response curve was bell-shaped with a peak at 2-4 mg/kg. At variance with other studies, 5-HT3 receptor antagonists also increased the number of shocks taken in this test and the dose-response curve was also bell-shaped. VA21B7 was not anticonvulsant like diazepam, its anxiolytic action in the light/dark test was not flumazenil-sensitive and there was no rebound anxiogenic effect on withdrawal from chronic VA21B7 treatment for 15 consecutive days. Moreover, VA21B7 was not amnesic like the benzodiazepines but low doses of 2-4 mg/kg reduced the memory deficits induced in rats by scopolamine. Much higher doses were necessary to decrease spontaneous motor activity in rats. Since VA21B7 appears to be well tolerated in rodents at high doses, we think that it is of potential interest as an anxiolytic in humans.